C yclooxygenase (COX) catalyzes the oxygenation and reduction of arachidonic acid, leading to the formation of hydroxy endoperoxide (prostaglandin H 2 [PGH 2 ]). PGH 2 serves as a substrate for discrete prostaglandin (PG) synthases, which give rise to PGs such as PGE 2 , PGF 2␣ , PGD 2 , PGI 2 , and thromboxane A 2 . There are 2 COX isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in almost all cell types and plays a role in physiological homeostasis. In contrast, COX-2 is normally absent but can be induced by different stimuli, such as inflammatory cytokines, in many cells. 1, 2 We have previously shown that in neonatal ventricular myocytes (NVMs), the induction of COX-2 by interleukin-1␤ (IL-1␤) results in the preferential production of PGE 2 . 3 Recent reports have shown that the capacity of various cell types to produce PGE 2 over other PGs depends not only on the induction of COX-2 but also on PGE 2 synthase (PGES). In some cell types, COX-2 and PGES are colocalized in a perinuclear distribution. 4 -6 The biological actions of PGE 2 are mediated through 4 specific G-coupled receptors, EP 1 , EP 2 , EP 3 , and EP 4 , which differ in structure, ligand-binding properties, activation of signal transduction pathways, and tissue distribution. 7 Although activation of EP 2 and EP 4 (coupled to G␣ s ) increases cAMP, EP 1 receptors mediate Ca 2ϩ mobilization. 7, 8 Studies in vivo and in vitro suggest that under normal conditions, the EP 3 receptor couples to either G␣ i or G␣ q , decreasing cAMP. 7, 9 Previous reports have shown acute upregulation of EP 3 receptors in the pig heart after myocardial infarction. 10, 11 Nevertheless, the role of EP receptors and their distribution in cardiac cells remains uncertain.
It has been suggested that prostanoids work at or near their site of production as autocrine and paracrine factors. 7 PGE 2 induces mitogenesis and tumor growth. [12] [13] [14] [15] Other studies have suggested that proinflammatory cytokines can induce hypertrophy in vitro and in vivo. 16 -20 IL-1␤ is induced in the heart in response to chronic pressure overload, ␤-adrenergic stimulation, and infarction. [21] [22] [23] Thus, in the present study, we examined the mechanisms by which myocytes produce high levels of PGE 2 , concentrating on IL-1␤ induction of PGES and localization of COX-2 and PGES within the cell. We also studied whether PGE 2 increases myocyte growth and the receptors that mediate its response.
Methods

Cell Culture
Primary cultures of NVMs were derived from the digestion of 1-to 2-day-old neonatal Sprague-Dawley rat hearts (Charles River, Kalamazoo, Mich), as described previously. 24 After 40 hours in culture with DMEM plus 10% FBS (Gibco), serum-free medium supplemented with glutamine, insulin, selenium, and transferrin (SF-DMEM) was then added for 24 hours. Neonatal cardiac fibroblasts were generated at the preplate stage of the myocyte preparation and passaged twice before use. 
Isolation of Protein and Western Blot
After medium was removed for the assay of prostanoids (see above), protein was isolated from cardiac myocytes by using lysis buffer and protease inhibitors and subjected to Western blot as described previously. 25 The 72-kDa COX-2 protein was detected as described previously, 26 whereas the 17-kDa PGES protein was detected in membrane-enriched preparations generated by ultracentrifugation of the cell lysate through a 7-mL cushion of 6% sucrose at 230 000g for 40 minutes. The pellet was resuspended in lysis buffer containing protease inhibitors. The 17-kDa PGES was detected with an antirabbit polyclonal antibody (Cayman) diluted 1:500. The appropriate secondary antibody linked to horseradish peroxidase (1:2000) was used for chemiluminescent detection with ECL Western blot reagents (Amersham Pharmacia Biotech). The signal was detected by exposure to Fuji RX film and quantified by laser densitometry.
EIA for cAMP
cAMP in NVM cell lysates was determined by EIA with the use of the low pH kit from R & D Systems, according to their instructions. NVMs (0.5ϫ10 6 ) were stimulated with vehicle, isoproterenol (ISO), sulprostone, or PGE 2 for 30 minutes in the presence of 1 mmol/L 3-isobutyl-l-methylxanthine to inhibit phosphodiesterase activity. Results were expressed as picomoles cAMP per 0.5ϫ10 6 cells. Triplicate values from 3 wells were averaged for each treatment in each separate experiment.
Isolation of RNA and RT-PCR
Total RNA was isolated from control and IL-1␤-treated NVMs with the use of Tri Reagent (MRC Inc) according to the manufacturer's instructions. Reverse transcription (RT) of total RNA (2 g) was performed in a total volume of 25 L by using 1 g random primer (Gibco-BRL) and 200 U MMLV reverse transcriptase (Promega). Aliquots (5 L) of the resulting cDNA were subjected to polymerase chain reaction (PCR) for amplification of COX-2 (462 bp), PGES (473 bp), and GAPDH (554 bp). Oligonucleotide primers (5Ј to 3Ј) for rat COX-2 were AGT ACG AAG ACC CTG CCT ACG (sense) and TAA GTT GGT GGG CTG TCA AT (antisense). Primers for the complete PGES cDNA were ATG ACT TCC CTG GGT TTG GTG (sense) and TCA GCT GCT GGT CAC AGA TGG (antisense). Primers for rat GAPDH were AAT GCA TCC TGC ACC ACC TGC (sense) and GGA GGC CAT GTA GGC CAT GAG GTC (antisense). A PTC-100 thermal controller (MJ Research, Inc) was used for amplification, and the program settings were denaturation for 30 seconds at 95°C, annealing for 60 seconds at 58°C, and extension for 90 seconds at 72°C for 40 cycles. PCR products were separated out on a 1.0% agarose gel, stained with ethidium bromide, and photographed.
Confocal Microscopy
Fifty thousand myocytes were plated on coverslips coated with fibronectin (10 g/mL) and grown in 10% serum. After substitution with SF-DMEM for 24 hours and treatment of the cells with 5 ng/mL IL-1␤ or vehicle for another 24 hours, they were washed twice with PBS and fixed in 4% paraformaldehyde in PBS for 15 minutes. Cells were then permeabilized in 0.1% Triton X-100 in PBS for 10 minutes and blocked for 1 hour in 1% BSA/Tris-buffered saline with 0.1% Tween (TBS-T). Cells were incubated with the primary antibody (diluted 1:100 in 1% BSA/TBS-T) for 60 minutes and then washed with TBS-T. The secondary antibody (donkey anti-goat and goat anti-rabbit Alexa fluor 488 for COX-2 and PGES, respectively) was diluted 1:2000 in 1% BSA/TBS-T and added to the cells for 45 minutes in the dark. After consecutive washes for 1 hour with TBS-T, samples were mounted in Fluoromount-G (Southern Biotechnology Associates). Coverslips were examined under oil immersion at ϫ63 magnification. Immunofluorescence was detected after excitation at 488 nm with use of a Bio-Rad MRC 1024 confocal laser scanning microscope.
Measurement of Protein Synthesis
Protein synthesis was determined by the incorporation of [ 3 H]leucine into trichloroacetic acid-insoluble material after 48 hours, as described previously. 27 NVMs were treated with phenylephrine (Phe), PGF 2␣ , PGE 2 , or beraprost for the experiments in Figure 4 , with sulprostone and AH6809 for the experiments in Figure 5 , and with cAMP for the experiments in Figure 6B . All treatments lasted 48 hours. For each treatment in each experiment, counts per minute from triplicate filters were averaged.
Statistical Analysis
Values are represented as meanϮSE. Differences in mean values were analyzed by 1-way ANOVA, with pairwise multiple comparisons made by the Student-Newman-Keuls method. A value of PϽ0.05 was considered significant.
Chemicals
PGE 2 , PGF 2␣ , beraprost, PGES antibody, AH6809, and sulprostone were obtained from Cayman. COX-2 antibody was obtained from Santa Cruz. L- [3,4,4- 3 H(N)]leucine was purchased from NEN/Dupont, and IL-1␤ was purchased from Collaborative Biomedical Products. Dibutyryl cAMP was purchased from Sigma Chemical Co. For confocal microscopy, secondary antibodies were obtained from Molecular Probes. All other laboratory supplies and chemicals were obtained from Sigma, Fisher, and VWR Scientific.
Results
Effect of IL-1␤ on Myocyte and Fibroblast PG Production
Experiments were conducted to characterize the profile of PGs released by myocytes and fibroblasts in the presence and absence of 5 ng/mL IL-1␤ for 24 hours. Basal production of each PG in untreated myocytes was in the range of 0.1 to 2 ng/mg protein, whereas in fibroblasts it was 1 to 5 ng/mg protein. In IL-1␤-stimulated NVMs, PGE 2 production was much higher than PGI 2 and PGF 2␣ production and exceeded the total PG production by fibroblasts ( Figures 1A and 1B) . In confluent cultures of neonatal cardiac fibroblasts (passage 3), the pattern of PG production was different from that in myocytes, with PGI 2 being the major product ( Figure 1B) . The robust production of PGs by myocytes and fibroblasts was accompanied by the induction of COX-2.
Effect of IL-1␤ on PGES Expression
Because of the high level of PGE 2 produced by NVMs and recent reports of PGES upregulation in response to inflammatory stimuli, 5,6,28 we questioned whether IL-1␤ also regulates PGES expression in cardiac myocytes. RT-PCR studies
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( Figure 2A ) indicate that IL-1␤ treatment of NVMs induced PGES mRNA (lane 6), in addition to COX-2 mRNA (lane 2), whereas untreated control NVMs did not express either gene product (lanes 1 and 5). We also amplified a signal for GAPDH mRNA from IL-1␤-treated and control NVMs (lanes 3 and 4) as a control for RNA integrity in our samples. PGES protein was detected by Western blot of a membraneenriched fraction of IL-1␤-treated NVMs, confirming the RT-PCR results ( Figure 2B ). Thus, PGE 2 production in NVMs requires coordinated regulation of both PGES and COX-2.
Subcellular Localization of COX-2 and PGES in Myocytes
Confocal microscopy was performed to determine the subcellular localization of COX-2 and PGES in NVMs. Separate coverslips were analyzed by confocal microscopy for immunofluorescence with the use of specific polyclonal antibodies for each inducible enzyme. In Figure 3 , immunofluorescence micrographs (panels D and H) and their corresponding transmittance views (panels C and G) are shown. Results from the examination of multiple coverslips indicate that both COX-2 and PGES were localized in a perinuclear distribution. Untreated cells incubated with both the primary and secondary antibodies were used as controls. When controls were examined under the same conditions that produced immunofluorescence for COX-2 and PGES, only background immunofluorescence was observed (panels B and F).
Effect of Exogenous PGE 2 on Myocyte Growth
COX-2 and/or its products have been associated with cell growth. 29 -31 In particular, PGE 2 has been found to be mitogenic in different cell types, [12] [13] [14] [15] although its role in the heart remains unclear. Because PGE 2 was produced in the greatest amount by myocytes, we questioned whether it plays a role in cell growth. Figure 4A shows that protein synthesis increased 1.6Ϯ0.1-fold when NVMs were treated with 1 mol/L PGE 2 for 48 hours. As positive controls, we used the known hypertrophic factors Phe (50 mol/L) and PGF 2␣ (1 mol/L), both of which produced a significant increase in protein synthesis comparable to that of PGE 2 (Phe 1.6Ϯ0.2-fold, PGF 2␣ 1.9Ϯ0.1-fold). As an additional control for nonspecific effects of PGs on growth, NVMs were treated for 48 hours with the PGI 2 analogue beraprost, which had no effect on protein synthesis ( Figure 4B ).
Involvement of EP Receptors in Protein Synthesis
To determine whether EP 1 and EP 3 are linked to growth in NVMs, pharmacological approaches were used. We first tested the effect of the EP 1 /EP 3 -selective agonist sulprostone on protein synthesis. Cardiac myocytes were treated with 1 mol/L sulprostone in the presence of [ 3 H]leucine for 48 hours. Sulprostone increased protein synthesis 1.7Ϯ0.1-fold, indicating that the activation of EP 1 and/or EP 3 receptors is hypertrophic ( Figure 5A ). Sulprostone was also stimulatory at 10 Ϫ8 mol/L (1.5Ϯ0.2-fold increase, nϭ6). We next tested the effect of the EP 1 /EP 2 antagonist AH6809. Figure 5A shows that treatment with 10 mol/L AH6809 in combination with sulprostone reduced protein synthesis by 43% (sulprostone 1.7Ϯ0.1-fold increase, sulprostoneϩAH6809 1.4Ϯ0.05-fold increase). Because sulprostone is specific for EP 1 and EP 3 receptors and because AH6809 blocks EP 1 /EP 2, , our data clearly implicate EP 1 . In addition, because the effect of AH6809ϩsulprostone was statistically different from that of AH6809 alone, our data suggest that the remaining portion of the effect of sulprostone involves EP 3 . Because PGE 2 can bind to all 4 EP receptors, we next investigated the effect of AH6809 on PGE 2 stimulation of protein synthesis. We reasoned that if PGE 2 stimulation of protein synthesis is inhibited by AH6809, similar to the pattern seen in Figure 5A , this would verify the involvement of EP 1 . On the other hand, if AH6809 has no effect, then this might suggest that PGE 2 preferentially acts on EP 3 and/or EP 4 in NVMs. Results in Figure 5B indicate that AH6809 was unable to inhibit protein synthesis in PGE 2 -stimulated NVMs, suggesting a role for EP 3 and/or EP 4 .
Because the previous data suggested that sulprostone and PGE 2 were acting through different receptor subtypes and, thus, through different signaling mechanisms, we tested the effect of both compounds on cAMP production. NVMs were treated with 1 mol/L PGE 2 sulprostone or with the ␤-adrenergic agonist ISO (10 mol/L) as a positive control and assayed for cAMP production after 30 minutes. Figure  6A shows that PGE 2 stimulated cAMP production to the same extent as did the positive control ISO (ISO 14.8Ϯ2.2-fold, PGE 2 12.3Ϯ1.5-fold). As expected, sulprostone had no effect on cAMP levels (control 0.9Ϯ0.2-fold, sulprostone 0.8Ϯ0.2-fold). Finally, we found that cAMP itself (1 mmol/L dibutyryl cAMP for 48 hours) stimulated protein synthesis in NVMs ( Figure 6B ). Thus, PGE 2 uses a signaling mechanism that is different from that of sulprostone, and this most likely involves EP 4 and cAMP production.
Discussion
We have previously shown that the proinflammatory cytokine IL-1␤ regulates the synthesis of COX-2 and generates PGE 2 in NVMs. 32 The present study extends our understanding of PG production and the regulation of COX-2 in the heart to the cardiac fibroblast, where COX-2 is also induced by an inflammatory stimulus, but the pattern of PG synthesis is different from that in myocytes. In fibroblasts, there is preferential release of PGI 2 . In contrast to fibroblasts, myocytes produce greater amounts of PGs in response to IL-1␤, and PGE 2 production vastly exceeds the production of all other PGs. Because of this, we concentrated the present study on PGE 2 and its effect on the cardiac myocyte.
In the present study, we demonstrate for the first time that PGES is upregulated by IL-1␤ in NVMs and is localized to a membrane-enriched subcellular fraction. In agreement with our data, recent studies have shown that PGES expression is markedly upregulated by proinflammatory stimuli in various cell types. 5, 6 PGES has been detected in both cytosolic and microsomal fractions within various cells. Cytosolic PGES is a constitutive enzyme capable of converting COX-1-derived PGH 2 to PGE 2 , whereas microsomal PGES is inducible. 33, 34 Studies have demonstrated that COX-2 and microsomal PGES are colocalized in the perinuclear envelope, suggesting coordinated biosynthetic activity between the enzymes. 33 We extended this observation to cardiac myocytes by use of immunofluorescence and confocal microscopy, clearly showing a perinuclear distribution of COX-2 and PGES after IL-1␤ treatment. Because COX-2 and PGES mRNA and protein are not present in untreated NVMs, we hypothesize that after IL-1␤ stimulation of their expression, they are targeted to microsomes/membranes in and around the nucleus, where they interact to produce high levels of PGE 2 . Because PGES is critical for the production of high levels of PGE 2 , this enzyme seems to play a role in the inflammatory 
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response that is as important as COX-2. Thus, molecular mechanisms that result in the induction of PGES need to be elucidated; furthermore, clarification of the protein-protein interactions may explain how these 2 enzymes are effectively regulated. Although there are not many studies examining the role of COX-2 in cell growth in the heart, there is considerable evidence indicating that COX-2 is involved in tumorigenesis. 12, 35 Nonsteroidal anti-inflammatory drugs have been shown to control the size of some tumors. 12, 29, 36 In addition, COX-2 has been implicated in the proliferation of smooth muscle cells. 31 Interestingly, PGE 2 has also been implicated in cell growth, in that HEK293 cells overexpressing COX-2 and PGES were found to grow rapidly. 33 The present study indicates that PGE 2 , but not PGI 2 , plays an important role in cardiac myocytes by inducing protein synthesis to an extent comparable to that of the known hypertrophic factors Phe and PGF 2␣ . Studies have shown that PGF 2␣ is a hypertrophic growth factor in vivo and in vitro, but studies of PGE 2 have not yielded clear-cut results. 37, 38 Some indirect evidence suggests the participation of PGE 2 in cardiac fibroblast growth after myocardial infarction, 39, 40 but these studies used nonselective COX inhibitors, so that the role of COX-2 could not be clearly ascertained. Preliminary studies from our laboratory suggest that PGE 2 analogues can stimulate fibroblast proliferation in vitro (authors' unpublished data, 2001).
Our sulprostone data indicate that EP 1 and EP 3 are hypertrophic in NVMs, whereas our PGE 2 data implicate EP 4 and possibly EP 3 . To definitively determine whether EP 4 and EP 3 play a role in PGE 2 -stimulated protein synthesis will require the use of pure EP subtype antagonists or studies in EP 3 and EP 4 knockout mice. In general, little is known about the type and role of the PG receptors in the individual cell types of the . cAMP production and its effects on protein synthesis. A, The y-axis shows cAMP levels expressed as picomoles per 0.5ϫ10 6 NVMs, and the x-axis shows treatment. NVMs were stimulated for 30 minutes in the presence of 3-isobutyl-1-methylxanthine (ISO, nϭ9; PGE 2 and SULP, nϭ3). *PϽ0.01 vs CTRL. B, The y-axis is identical to the y-axes in Figure 5 , and the x-axis shows treatment with cAMP. *PϽ0.01 vs CTRL (nϭ9).
heart. The presence of mRNA for the 4 EP receptors in a variety of adult mouse tissues has been examined, and it was found that in whole heart homogenates, EP 3 and EP 4 were expressed, although EP 4 mRNA was more abundant than EP 3 mRNA. 41 The fact that EP 1 mRNA was not detected in the adult mouse heart may simply reflect the relative insensitivity of the Northern blot for measuring low-abundance mRNAs or differences in the regulation of EP 1 in neonatal and adult rodent hearts. In fact, preliminary data from our laboratory indicate that EP 1 , EP 3 , and EP 4 can be detected by Western blot of membrane-enriched preparations of NVMs (authors' unpublished data, 2001). Although EP receptors are present in plasma membranes, perinuclear distribution has been found. 42, 43 Given that PGs are rapidly degraded and that COX-2 and PGES are clearly perinuclear, PGE 2 may also act via intracellular EP receptors. At this point, we have not determined whether the EP receptors are localized to specific subcellular compartments.
EP receptors belong to the family of 7-transmembranedomain receptors, which couple to large heterotrimeric G proteins. EP 2 and EP 4 are coupled to G␣ s and result in increases in cAMP, whereas EP 3 couples to G␣ i , and EP 1 is linked to increased intracellular calcium. G␣ i has been shown to couple to pathways involved in growth, including the activation of mitogen-activated protein kinase. 44 Activation of both G␣ s and G␣ i has been linked to increased protein synthesis in cardiac myocytes in vitro. 45, 46 It is well known that EP 1 increases intracellular calcium, and there is evidence indicating that increases in calcium are coupled to growthpromoting pathways, including activation of protein kinase C, calcium-calmodulin protein kinase, and calcineurin. 47, 48 Given that we have implicated EP 1 and EP 3 in myocyte hypertrophy in vitro, it would be interesting to determine whether there is chronic upregulation of these receptors in pathophysiological processes in the heart, such as pressure overload and infarction.
In summary, the present study has characterized molecular events underlying the very large increase in PGE 2 in myocytes after IL-1␤ treatment and has implicated an inducible PGES localized to a membrane-enriched fraction in this process. Moreover, COX-2 and PGES are localized in a perinuclear distribution in myocytes, which may be critical for the coupling of PGH 2 with PGE 2 synthesis. The present study also indicates that EP 1 , EP 3 , and EP 4 are involved in the regulation of protein synthesis. Thus, we believe that in addition to COX-2, PGES and EP receptors could serve as novel therapeutic targets for inflammation, cell growth, and remodeling in the heart.
